Grail
Researchers Stress Specificity of Grail Multi-Cancer Detection Test in Response to Study Criticism
Premium
The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Top Five Articles on 360Dx Last Week: Lab Co-Owner Sentenced; Alzheimer's Test Comparison; More
Last week, readers were most interested in a story about a lab co-owner who was sentenced to jail time and fined for his role in a fraudulent billing case.
Grail to Cut Headcount by 30 Percent in Restructuring, Reports 43 Percent Q2 Revenue Rise
Reporting its financial results as a separate company for the first time since its spinoff from Illumina, Grail said the restructuring will save it $27 million this year.
BMJ Report Reveals UK Officials' Concerns Over Grail Test Effectiveness, Trial Design
The report also mentions a US investor class action lawsuit that alleges Illumina and Grail officials oversold Galleri's potential.